메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

킴벌리클라크, 전 세계 2400만 여성과 소녀를 위한 필수 돌봄 강화 글로벌 파트너십 발표

댈러스, 2025년 10월 9일 -- 킴벌리클라크 코퍼레이션(Kimberly-Clark Corporation)(나스닥: KMB)이 여성과 소녀를 위한 필수 돌봄을 발전시키기 위한 노력을 강화하기 위해 네 가지 강화된 전략적 자선 파트너십을 체결했다. 킴벌리클라크는 베이비투베이비(Baby2Baby), 플랜 인터내셔널(Plan International), 프로젝트 HOPE(Project HOPE), 유니세프(UNICEF)와의 이 새로운 프로그램을 통해 브라질, 페루, 중국, 인도, 인도네시아, 베트남, 미국에서 삶의 변화를 가져올 수 있는 돌봄에 대한 접근성을 확대할 계획이다. 이번 파트너십은 향후 3년간 약 2400만 명의 여성과 소녀들의 삶을 개선하는 데 기여할 것으로 기대된다. 전체 인터랙티브 멀티채널 뉴스 보도는 여기서 확인할 수 있다. https://www.multivu.com/kimberly-clark/9238951-en-kimberly-clark-global-partnerships-women-and-girls 이번 발표는 킴벌리클라크 재단(Kimberly-Clark Foundation)이 최근 전략적 초점을
- 김갑성 기자
- 2025-10-09 21:05
LuX-Valve Plus Approved for Hong Kong-Macao Medicine a…

BEIJING, Oct. 9, 2025 -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with comprehensive structural heart disease interventional solutions, recently announced that LuX-Valve Plus transjugular tricuspid valve replacement system, the product of its subsidiary Jenscare Scientific (Netherlands) B.V., has been officially approved to be included in the Medical Device Catalog of Hong Kong-Macao Medicine and Equipment Connect, enabling commercial clinical application in designated medical institutions in mainland of
- 김갑성 기자
- 2025-10-09 21:00
Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets…

[ 메디채널 김갑성 기자 ] The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, supporting an early New Drug Application (NDA) submission World-first regimen in gastric cancer that replaces adjuvant chemotherapy with mono-immunotherapy in the perioperative setting The ASTRUM-006 study demonstrated a significant improvement in event-free survival (EFS) and achieved a more than threefold higher pathological complete response (pCR) rate compared with the control arm, unlocking the potential for a cure SHANGHAI, Oct. 9, 2025 -- Sha
- 김갑성 기자
- 2025-10-09 20:50
Field Medical First-in-Human 6-Month Data Selected for Late-B…

Three sessions feature new outcomes, a live case, and preclinical research with the FieldForce™ Ablation System. CARDIFF-BY-THE-SEA, Calif., and PHILADELPHIA, Oct. 9, 2025 -- Field Medical, Inc., a leader in pulsed field ablation (PFA) technology for ventricular tachycardia (VT), today announced its participation at the 20th Annual International Symposium on Ventricular Arrhythmias (VT Symposium), taking place Oct. 10 –11 in Philadelphia. Field Medical will be featured across three sessions, including first-in-human six-month outcomes from its FieldForce™ Ablatio
- 김갑성 기자
- 2025-10-09 20:33
Samsung Biologics Introduces Optimized Manufacturing Fra…

ExellenS TM applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed ExellenS TM combines the company's commitment to operational excellence with its core manufacturing competencies, guided by standardization, simplification, and scalability ExellenS TM delivers faster tech transfers, rapid approvals, predictable outcomes, and global flexibility for clients INCHEON, South Korea, Oct. 9, 2025 -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today unveiled Exe
- 김갑성 기자
- 2025-10-09 19:00
Chance Pharma Announces Commercialization Agreement…

HANGZHOU, China, Oct. 9, 2025 -- Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced that it has reached an exclusive commercialization agreement with Huadong Medicine (Hangzhou) Co., Ltd., a wholly owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), to commercialize CXG87 in Mainland China. Under the terms of the agreement, Chance Pharma, as the MAH (Marketing Authorization Holder), will be res
- 김갑성 기자
- 2025-10-09 17:27
Advantech AOM-5721 Combines SMARC Design and Qualcomm…

TAIPEI, Oct. 9, 2025 -- Advantech (TWSE: 2395), a global leader in edge computing and AI solutions, is proud to announce the launch of the AOM-5721, a SMARC-based Arm Computer-on-Module powered by the Qualcomm® Dragonwing™ QCS6490 SoC. By combining Advantech's expertise in compact, energy-efficient computing modules with Qualcomm's high-performance SoC, the AOM-5721 delivers cutting-edge AI processing, connectivity, and multimedia capabilities for industrial, commercial, and medical edge applications. Engineered for Intelligent Performance The Qualcomm Dragonwing™ QC
- 김갑성 기자
- 2025-10-09 17:05
BTL, WonderFace 기기 제조사를 상대로 특허 침해 소송 제기

프라하 , 2025년 10월 9일 -- 의료 솔루션 분야를 선도하는 글로벌 기업인 BTL 그룹(BTL Group)은 오늘 WonderFace 기기 제조사인 렉스터 마이크로일렉트로닉 엔지니어링 시스템 S.L(Lexter Microelectronic Engineering Systems S.L)을 상대로 통합 특허 법원에 국제 특허 침해 소송을 제기했다고 발표했다. 이번 소송은 BTL의 EMFACE® 기술 특허에서 시작되었다.1 EMFACE® 기술은 별도의 핸즈-프리 어플리케이터로 선별적 근육 자극과 고주파 가열을 결합하여 안면 리프팅 시술에 혁명을 일으킴으로써 완전히 새로운 안면 시술 카테고리를 열었다는 평가를 얻고 있다. BTL 엔터프라이즈 그룹 CEO 토마스 슈바르츠(Tomas Schwarz)는 "우리는 지적 재산을 단호히 방어하여 고객의 투자를 보호할 계획이다. 이번 소송은 우리의 혁신 기술을 침해하는 제3자를 상대로 법적 소송을 넓혀 나가는 신호탄이 될 것이다."라고 밝혔다. 이번 소송은 WonderFace 시스템이 다수의 국가로 배포되는 것을 막는 데 목적이 있다. 소
- 김갑성 기자
- 2025-10-09 16:01
Dymax's New 9773 Ruggedized Adhesive Meets NASA ASTM E595…

[ 메디채널 김갑성 기자 ] Material Provides Protection Solution for Mission-Critical Components and Board-Level Electronics in Space Applications SINGAPORE, Oct. 9, 2025 -- Dymax, a leading manufacturer of rapid and light-curing materials and equipment, is pleased to add 9773 ruggedizing and staking adhesive to its portfolio of materials designed for coating, protecting, and securing components on printed circuit boards in satellites, missiles, and space applications. Dymax 9773 is certified to NASA ASTM E595 Low Outgassing and meets Mil-Std 883 Method 5011 Low Ionic Content standards,
- 김갑성 기자
- 2025-10-09 15:55
Herbalgy, the Pain Management Expert, Partners with Heroes i…

Bringing the Wisdom of Traditional Chinese Medicine into Modern Living HONG KONG, Oct. 9, 2025 -- Following the phenomenal success of TVB's widely acclaimed TV drama Heroes in White—the top-rated series of 2025 with an audience of over 1.57 million and a rating of 24.2 points—Herbalgy, the trusted Pain Management Expert, is extending the show's inspiring message from screen to everyday life. The drama, initiated by TVB, was inspired by the extraordinary real-life experiences of Professor Wong Tin Chee, founder of Herbalgy. Professor Wong's dedication to advancing
- 김갑성 기자
- 2025-10-09 14:18

이전

71 72 73 74 75 76 77 78 79 80

많이 본 기사

최근기사

2025-12-13_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 13일 23시 40분